Emergent Biosolutions Inc
$ 12.05
3.88%
04 Dec - close price
- Market Cap 642,881,000 USD
- Current Price $ 12.05
- High / Low $ 12.28 / 11.52
- Stock P/E 9.13
- Book Value 11.05
- EPS 1.32
- Next Earning Report 2026-03-10
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA 0.05 %
- ROE 0.14 %
- 52 Week High 13.41
- 52 Week Low 4.02
About
Emergent BioSolutions Inc. (EBS), based in Gaithersburg, Maryland, is a prominent life sciences company focused on advancing public health preparedness through innovative solutions for both civilian and military sectors. The firm specializes in the development and manufacturing of vaccines, therapeutics, and diagnostics that address critical public health threats, including emerging infections and bioterrorism. With a strong commitment to health security and a diverse product portfolio, Emergent is well-positioned to respond to urgent global health challenges and support governmental emergency response initiatives.
Analyst Target Price
$13.50
Quarterly Earnings
| Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2025-10-29 | 2025-08-06 | 2025-04-29 | 2025-03-04 | 2024-11-06 | 2024-08-06 | 2024-05-01 | 2024-03-06 | 2023-11-08 | 2023-08-08 | 2023-05-09 | 2023-02-27 |
| Reported EPS | 1.06 | 0.16 | 0.71 | -0.5775 | 1.37 | -2.32 | 0.59 | -0.77 | -0.54 | -1.06 | -3.17 | -0.31 |
| Estimated EPS | 0.0467 | -0.1 | 0.7 | -0.4957 | 0.14 | -0.94 | -0.86 | -0.19 | -0.22 | -0.49 | -1.24 | 0.04 |
| Surprise | 1.0133 | 0.26 | 0.01 | -0.0818 | 1.23 | -1.38 | 1.45 | -0.58 | -0.32 | -0.57 | -1.93 | -0.35 |
| Surprise Percentage | 2169.8073% | 260% | 1.4286% | -16.5019% | 878.5714% | -146.8085% | 168.6047% | -305.2632% | -145.4545% | -116.3265% | -155.6452% | -875% |
Next Quarterly Earnings
| Dec 2025 | |
|---|---|
| Reported Date | 2026-03-10 |
| Fiscal Date Ending | 2025-12-31 |
| Estimated EPS | 0.425 |
| Currency | USD |
Previous Dividend Records
| Jan 1970 | |
|---|---|
| Payment Date | None |
| Amount | $1.855 |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: EBS
2025-10-17 20:02:38
Emergent BioSolutions Inc.'s EVP and CFO reported an administrative transaction involving the withholding of 4,995 common shares at $9.60 each to cover taxes related to the vesting and settlement of restricted stock units. Following this transaction on October 15, 2025, the officer directly beneficially owns 291,497 shares of EBS. The filing sentiment is noted as low impact and negative.
2025-10-16 19:30:16
A new severe Mpox strain case has been identified in California, highlighting the ongoing public health need for countermeasures. This article provides a financial analysis of Emergent BioSolutions Inc. (EBS), a biotechnology company specializing in public health products, detailing its market position, financial health, valuation, and risk assessment.
2025-10-08 11:50:00
Emergent BioSolutions Inc. will host a conference call on October 29, 2025, at 5:00 PM eastern time to discuss its financial results for the third quarter of 2025. Interested participants can access the call via a live webcast on the company's Investors page or register for telephone participation. The company highlights its long-standing commitment to public health.
2025-10-08 00:00:00
Emergent BioSolutions Inc. (NYSE:EBS) shares have recently jumped 31% over the last month, though its annual return is less impressive at 7.6%. Despite the bounce, the company's price-to-sales (P/S) ratio of 0.6x remains significantly lower than the industry average, which is attributed to its declining revenue and a forecast of slower growth compared to the wider Biotech industry. Investors appear to be factoring in a less prosperous future for the company, leading to its subdued P/S.
2025-09-26 00:00:00
Emergent BioSolutions Inc. (NYSE:EBS) has seen its stock rise 10% over the past week, bringing its one-year return to 20%, much to the benefit of its large institutional owners who hold 68% of the company. BlackRock, Inc. is the largest shareholder with 8.2%, and institutions collectively wield significant power over the company's direction. Insiders own 0.6% of the company, valued at US$12 million.
2025-09-19 08:34:00
Emergent BioSolutions (NYSE:EBS) has secured new purchase orders totaling $29 million from an international government partner for medical countermeasures (MCMs), including products for smallpox, anthrax, and botulism. The company anticipates receiving $26 million in 2025, adding to over $100 million in year-to-date sales for its MCM portfolio outside the U.S. This marks the second procurement by the same government this year, signaling a strengthening relationship and aligning with increased global defense spending, particularly among NATO members.
